Current recommendations are to follow molecular MRD in the setting of APL(PML-RARα), CBF-AML (RUNX-RUNX1T1; CBF-MYH11) and NPM1- mutated AML. The gene discussed is CEBPZ; the disease is acute myeloid leukemia.